OPHTHALMIC RESULTS IN PATIENTS WITH MACROPROLACTINOMAS TREATED WITH ANEW PROLACTIN INHIBITOR CV-205-502

Macroprolactinomas are pituitary tumours which have been effectively t reated medically since the introduction of bromocriptine. The visual f unction of 13 patients treated with a new prolactin (PRL) inhibitor CV 205-502 (Sandoz Basle), a potent and selective dopamine D2 receptor a gonist, was evaluated. This is the first detailed ophthalmic report of the use of this drug in macroprolactinomas. Patients were enrolled fr om June 1988 to July 1990 (mean follow up 30 months). Visual function including visual acuity, ocular pressure, and visual fields was regula rly controlled. Visual fields (VF) were tested with Goldmann and autom atic static perimetry (Vision Monitor). Treatment was globally effecti ve. No modifications of the visual function were observed in nine pati ents (six normal, three previous VF losses after surgery). In four oth er patients, visual function dramatically improved (regression of a II I paresis, one case; disappearance of a chiasmatic syndrome, three cas es). A pituitary necrosis was observed in one case and successfully cu red. CV 205-502 seems to be an effective and well tolerated treatment of macroprolactinomas.